BD completes TriPath purchase
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson completes $350 million purchase of TriPath Imaging following TriPath shareholder approval Dec. 19. TriPath's SurePath cervical cancer screening technology and molecular oncology diagnostics dovetail with BD's flow cytometry systems for detection of lymphoma and leukemia and advance BD's position in cancer diagnostics. The firms inked a definitive deal last September (1"The Gray Sheet" Aug. 21, 2006, p. 3)...